Stocksigma LogoStocksigma Logo

Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions

Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196.1 crore, rising 9.0% QoQ, driven by operational efficiencies that expanded gross margin to

Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions

Sai Parenterals Ltd 路 Press Release 路 01 Nov 2026, 11:48 pm

Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196.1 crore, rising 9.0% QoQ, driven by operational efficiencies that expanded gross margin to 47.5%. EBITDA surged 67.4% QoQ to Rs. 41.4 crore with margins at 21.1%, while PAT reached Rs. 10.5 crore despite higher depreciation. H1FY27 revenue stood at Rs. 376.0 crore, tracking at 50% of the full-year Rs. 750 crore target. Unit III expansion completed, boosting monthly capacity by 81% to 155 million units, alongside acquiring 60% stakes in Saicriti Pharma and Sai Prathyak Laboratories.

Original exchange filing (PDF)

More announcements from Sai Parenterals Ltd

All Sai Parenterals Ltd announcements